Recent News

• 02.13.2026 - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
• 02.12.2026 - OKYO Pharma Announces Public Offering of Ordinary Shares
• 02.11.2026 - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
• 02.10.2026 - OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
• 01.30.2026 - OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Recent Filings

• 02.12.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2026 - EX-99.1 EX-99.1
• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.11.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.10.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.10.2026 - EX-99.1 EX-99.1